Last reviewed · How we verify
Dyspepsia Prevention — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Pepcid | famotidine | Generic (originally Yamanouchi/Merck) | Histamine-2 Receptor Antagonist [EPC] | Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 | 1986-10-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Pepcid · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Yamanouchi/Merck) · 1 drug in Dyspepsia Prevention
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Dyspepsia Prevention:
- Dyspepsia Prevention treatment updates — RSS
- Dyspepsia Prevention treatment updates — Atom
- Dyspepsia Prevention treatment updates — JSON
Cite this brief
Drug Landscape (2026). Dyspepsia Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dyspepsia-prevention. Accessed 2026-06-10.
Related
- Dyspepsia Prevention full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing